Assert-IQ vs Bunkerhill ECG-EF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Abbott
VS
by Bunkerhill Health

AI Verdict

Assert-IQ is an insertable cardiac monitor system designed for long-term, continuous arrhythmia detection and management. In contrast, Bunkerhill ECG-EF is a software-only AI algorithm that analyzes routine 12-lead ECGs to identify patients at risk for reduced left ventricular ejection fraction and heart failure. While both are cardiology AI tools, they serve distinct diagnostic purposes, with Assert-IQ focusing on rhythm disorders and Bunkerhill ECG-EF on heart failure risk.

Choose Assert-IQ if…

Choose Assert-IQ if your patient requires long-term, continuous monitoring for suspected, infrequent, or asymptomatic arrhythmias that may not be captured by traditional short-term methods. This insertable cardiac monitor is ideal for comprehensive, multi-year surveillance to diagnose and manage complex heart rhythm disorders effectively.

View Assert-IQ →

Choose Bunkerhill ECG-EF if…

Choose Bunkerhill ECG-EF if you need a rapid, non-invasive, and accessible screening tool to identify patients at risk for heart failure by detecting reduced left ventricular ejection fraction from routine 12-lead ECGs. This AI algorithm is particularly useful for integrating into existing clinical workflows to efficiently screen large patient populations or those presenting with non-specific symptoms.

View Bunkerhill ECG-EF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Assert-IQ Bunkerhill ECG-EF
Pricing Unknown Contact sales for pricing details.
Deployment Subcutaneously implanted device with mobile app connectivity Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs.
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill ECG-EF

Bunkerhill ECG-EF is a software-only, non-invasive tool that analyzes routine ECG data, requiring no patient procedure. Assert-IQ, while offering remote monitoring post-implantation, necessitates a minimally invasive insertion. Bunkerhill's seamless EHR integration and automated workflows, including conversational AI for clinicians, offer a superior overall usability experience for both patients and healthcare providers.

Clinical Value

Tie

Both tools offer significant, yet distinct, clinical value. Assert-IQ provides long-term, continuous monitoring for arrhythmias, improving diagnosis and management of episodic heart rhythm disorders. Bunkerhill ECG-EF offers a highly accessible, non-invasive screening for reduced LVEF from routine ECGs, addressing a critical need for early heart failure identification in a broad patient population.

Pricing & Value

Tie

Neither tool provides transparent public pricing, both requiring direct contact for institutional quotes. Without specific cost information or comparative cost-benefit analyses, it is impossible to definitively determine which offers better overall pricing and value. While Bunkerhill ECG-EF has a noted CMS reimbursement pathway, this alone does not establish superior value without knowing the actual costs.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, being FDA cleared and HIPAA compliant with robust integration capabilities. Assert-IQ benefits from Abbott's extensive history and global infrastructure. Bunkerhill ECG-EF, while from a smaller company, emphasizes seamless EHR integration, automated workflows, and strong security protocols, making it highly suitable for large-scale enterprise deployment.

Innovation

Bunkerhill ECG-EF

While Assert-IQ incorporates advanced AI and offers industry-leading battery life for ICMs, Bunkerhill ECG-EF demonstrates a more disruptive innovation. It leverages AI to extract novel diagnostic information (reduced LVEF) from routinely collected, non-invasive ECG data for widespread heart failure screening. Its broader Carebricks platform, utilizing generative AI for clinical reasoning and action across diverse data sources, further highlights its innovative approach to transforming clinical workflows.

Support & Docs

Assert-IQ

Abbott Medical, as a large and established global medical device manufacturer, provides extensive and well-documented support resources for Assert-IQ, including comprehensive manuals, guides for healthcare professionals, and dedicated patient support services like SyncUP. While Bunkerhill Health likely offers support for its software, the sheer scale and history of Abbott suggest a more robust and comprehensive support and documentation ecosystem.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Assert-IQ Bunkerhill ECG-EF
Name Assert-IQ Bunkerhill ECG-EF
Company Abbott Medical BunkerHill Health
Description The Assert-IQ™ Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. Bunkerhill ECG-EF is an FDA-cleared artificial intelligence algorithm by BunkerHill Health that detects reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure.
Key Features Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetooth® Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion AI algorithm to detect reduced Left Ventricular Ejection Fraction (LVEF ≤ 40%), Analyzes routine 12-lead ECG data, Software-only medical device, Integrates with Electronic Medical Records (EMR) or ECG Management Systems (EMS), Part of the Carebricks platform for clinical reasoning and action, Aids in early identification of patients at risk for heart failure, Non-invasive, rapid, and accessible cardiac diagnostic tool, Supports automated clinical workflows
Categories Cardiology AI, Clinical Decision Support & Reference Cardiology AI
Specialties Cardiology, Internal Medicine Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Bunkerhill ECG-EF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Assert-IQ is designed for long-term, continuous cardiac monitoring and advanced arrhythmia detection to diagnose and manage patients with suspected heart rhythm disorders. Bunkerhill ECG-EF is an AI algorithm that detects reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead ECGs, aiding in the early identification of patients at risk for heart failure.
Assert-IQ utilizes a minimally invasive insertable cardiac monitor that provides continuous, long-term data collection for up to six years. In contrast, Bunkerhill ECG-EF is a software-only medical device that analyzes data from routine 12-lead electrocardiograms.
Assert-IQ requires a minimally invasive insertion procedure to implant the cardiac monitor under the skin. Bunkerhill ECG-EF is a non-invasive software algorithm that analyzes existing ECG data, requiring no additional patient procedures.
Assert-IQ features a secure cloud-based data platform and remote monitoring capabilities, with a hybrid deployment model that includes remote programmability. Bunkerhill ECG-EF integrates seamlessly with Electronic Medical Records (EMR) or ECG Management Systems (EMS) to support automated clinical workflows.
Assert-IQ provides long-term, continuous cardiac monitoring for up to six years, with options for three or six-year battery life. Bunkerhill ECG-EF offers a rapid, non-invasive analysis of routine 12-lead ECGs for a point-in-time assessment of heart failure risk.
Assert-IQ is intended for patients susceptible to cardiac arrhythmias and unexplained symptoms, or those already diagnosed with atrial fibrillation, requiring long-term, continuous monitoring. Bunkerhill ECG-EF aids in the early identification of adults at risk for heart failure by detecting reduced LVEF from routine ECGs, but it is not for patients already diagnosed with heart failure or for continuous monitoring.
AI Tool Finder
AI-powered search. Results may not be comprehensive.